Sentences with phrase «cell therapies aim»
This spotlight on cell therapy regulation will aim to provide insight into challenges, trends, developments and debates in the regulation of cell therapies aimed at regenerative medicine applications.
https://www.regmednet.com/ Not exact matches
Human Longevity has already received $ 70 million in private backing and aims to use both genomics and stem cell therapies to allow us to live longer, healthier lives.
They rule out selective abortion of defective fetuses, and they focus our attention on therapies aimed at somatic cells rather than germ cells.
With this distinction in mind some have drawn a line between intervention aimed at somatic cell therapy and intervention aimed at germ cell therapy.
Researchers at the Center for Engineering MechanoBiology (CEMB), an NSF Science and Technology Center at the University of Pennsylvania, study plants like this Arabidopsis thaliana to learn how molecules, cells and tissues integrate mechanics within plant and animal biology, with the aim of creating new materials, biomedical therapies and agricultural technologies.
Most cancer therapies are aimed at halting cancer growth by stopping cells from rapidly dividing.
Investigations aimed at determining the downstream targets of LIF would help to clarify the functional importance of LIF in muscle regeneration, and further its potential application in cell transplantation therapy.»
A new wave of potential immune therapies aims to target the network of complex sugars that coat cancer cells, Esther Landhuis reported in «Cancer's sweet cloak» (SN: 4/1/17, p. 24).
Clinical trials that charge enrollees to participate are ostensibly aimed at giving patients early access to promising therapies — often in the fields of stem cells or aging reversal — that are too unusual or have too little profit potential to get funding from traditional sources such as companies, foundations, or the National Institutes of Health.
The aim of most anticancer therapies is to eradicate all cancer cells from the body so that the cancer can not regrow.
«Now that we've identified where the replication - competent virus is hiding, we can start work towards targeting these cells with new therapies aimed at fully eliminating HIV from the body,» Associate Professor Palmer concluded.
«Identifying targets essential to cell survival in tumor suppressor genes has long been an investigational goal with the aim of offering cancer - specific vulnerabilities for targeted therapy,» said Ronald DePinho, M.D., professor of Cancer Biology, MD Anderson president, and senior author for the Nature paper.
«This groundbreaking study sets the stage for more exacting research, using the latest genomic technologies and aimed at developing new therapies that could help the tens of thousand of patients who urgently need our help,» said Dr. Nhan Tran, an Associate Professor of TGen's Cancer and Cell Biology Division and the study's other co-senior author.
«New way to unmask melanoma cells to the immune system: Lab studies show promise for a clinical trial aimed at improving current immune therapies.»
The scientists in Augustin's laboratory consequently pursued preclinical tumor therapy experiments, which were aimed at not just blocking angiogenesis, but to also suppress the production of tumor - promoting growth factors in endothelial cells.
A gene - therapy technique that aims to prevent mothers from passing on harmful genes to children through their mitochondria — the cell's energy - producing structures — might not always work.
Taken together, these observation impinge on one central problem: the development of rational targeting strategies aimed at overcoming therapeutic resistance require the precise elucidation of the molecular mechanisms whereby carcinoma cells that undergo EMT acquire the functional traits that render them resistant to conventional therapy.
It is also funding research aimed at a stem cell - based therapy for Parkinson's disease that is expected to lead to a clinical trial.
The strategy developed by research teams and development of I - Stem aims to identify innovative therapies applicable to rare genetic diseases based on exploring the potential offered by human pluripotent stem cells.
It aims at producing cell lines that are to be broadly available for manufacturing cell therapies matching the widest possible number of récipients.
Her aim is to understand, at the molecular level, the mechanisms that control communication between the brain, immune system, and blood vessels — with the ultimate goal of designing new therapies that slow, stop, or reverse the progression of a wide range of neurological disorders, such as MS. Recently, Dr. Akassoglou's lab identified how microglia — a type of immune cell that acts as the brain's first line of defense — are activated when fibrinogen enters the brain or spinal cord.
He is leading a trial in Europe to use fetal cells to treat patients, with the aim of «putting cell therapies for Parkinson's disease back on the map.»
Therapeutic strategies aiming at restoring the function of the implicated genes (gene and cell therapies) are very encouraging but not applicable in a near future to the variety of MDs.
The cell processing track aims at reproducible, safe and sustainable methods applicable in manufacturing settings for cell - based products intended for cellular therapy.
The insights we expect to gain from this study of mitochondria dysfunction and microRNAs, and what they tell us about how some RPE cells become diseased while neighboring cells are either resistant or susceptible to disease, hold promise of becoming the basis for entirely new therapies for individuals suffering from AMD, built upon nucleic acid - based treatments aimed at rejuvenating RPE cell mitochondria.
Recently, research efforts have concentrated on cell - based therapies for CLI that aim to improve limb perfusion by enhancing neovascularization.
The Asterias cell therapy platform for cancer immunotherapy aims to stimulate the body's ability to recognize cancer antigens and mount an immune response to control the spread of the disease.
Thus, our projects addressing beta cell function aim to reveal the underlying mechanisms of functional compensation and beta cell dysfunction to protect and recover beta cell function in diabetes therapy.
LifeMap Discovery provides information related to cell - based therapies, which aim to apply stem, progenitor or primary cells towards treatment of degenerative diseases.
Still, laying siege to cancer cells» supply lines may cast a wider net than targeted therapies aimed at rare oncogenic mutations.
Their results, published online May 5 by the journal Cell Stem Cell, could help better inform therapies aimed at neurocristopathies, diseases caused by defects in the neural crest or neurons, which include microphthamia and CHARGE syndrome.
Gene therapy and cell therapy are overlapping fields of biomedical research that aim to repair the direct cause of genetic diseases.
Chemotherapy can affect the whole body, but targeted therapy is aimed at a specific part of the cancer cell.
This will create strong synergy for a unified, multidimensional project aimed at generating more effective CAR T cells therapy for pancreatic cancer patients, with potential broad implications for immunotherapy directed toward other cancers.
Stem Cell Assays is a collaborative project of stem cellresearchers and cell therapy experts aiming to promote the stem cell fiCell Assays is a collaborative project of stem cellresearchers and cell therapy experts aiming to promote the stem cell ficell therapy experts aiming to promote the stem cell ficell field.
The FLI investigates the molecular causes for these aging - associated changes with the goal to uncover new approaches for therapies aiming to preserve the functioning of the body's own stem cells and organs thereby reducing the risk of diseases and cancer during aging.
Given our extensive experiences in neuronal differentiation of hESCs [6], [7], [8] and the potential application of hESC - derived neurons in cell replacement therapies for neurodegenerative diseases, we designed a set of experiments aimed at developing a hESC - based automated assay for screening small molecules that have differential toxicity to hESC - derived NSCs and their differentiated neural progenies.
One possible implication of this work is for so - called «gene - silencing» therapies for Huntington's disease, which aim to reduce production of the huntingtin protein, by sticking to its RNA message molecules and telling cells to get rid of them.